TPWA
PACB icon

Twin Peaks Wealth Advisors’s Pacific Biosciences PACB Stock Holding History

Twin Peaks Wealth Advisors’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-158
Closed -$209 – 1595
2026
Q1 		$209 Buy
+158
New +$283 ﹤0.01% 2166

Other funds holding PACB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Twin Peaks Wealth Advisors's PACB Position: Q2 2026 in Review

Twin Peaks Wealth Advisors sold out of Pacific Biosciences (PACB) in Q2 2026, closing a stake of 158 shares — an estimated $209 sold.

Twin Peaks Wealth Advisors first reported a position in PACB in Q1 2026 and held it in 1 quarter. The position peaked at $209 in Q1 2026. 223 funds tracked by Wall St. Rank hold PACB as of Q2 2026.

  • Twin Peaks Wealth Advisors reported no remaining Pacific Biosciences position as of Q2 2026 after selling out during the quarter.
  • Twin Peaks Wealth Advisors sold 158 Pacific Biosciences shares in Q2 2026, an estimated $209.
  • Twin Peaks Wealth Advisors first reported a position in Pacific Biosciences in Q1 2026 and held it in 1 quarter.
  • Twin Peaks Wealth Advisors's Pacific Biosciences position peaked at $209 in Q1 2026.
  • 223 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2026.

Based on Twin Peaks Wealth Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.